Schrodinger
Founded Year
1990Stage
IPO | IPOTotal Raised
$162MDate of IPO
2/6/2020Market Cap
1.71BStock Price
25.63About Schrodinger
Schrodinger provides advanced molecular simulations and enterprise software solutions and services for life sciences and materials research. Schrodinger also establishes partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company Nimbus Therapeutics.
Schrodinger Headquarter Location
120 West 45th Street 17th Floor
New York, New York, 10036,
United States
503-299-1150
Research containing Schrodinger
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Schrodinger in 2 CB Insights research briefs, most recently on Feb 12, 2020.

Expert Collections containing Schrodinger
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Schrodinger is included in 5 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Digital Health
12,812 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
2,246 items
This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.
Schrodinger Patents
Schrodinger has filed 7 patents.
The 3 most popular patent topics include:
- Computational chemistry
- Drug discovery
- Physical chemistry
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
8/22/2017 | 7/28/2020 | Computational chemistry, Statistical mechanics, Drug discovery, Physical chemistry, Thermodynamics | Grant |
Application Date | 8/22/2017 |
---|---|
Grant Date | 7/28/2020 |
Title | |
Related Topics | Computational chemistry, Statistical mechanics, Drug discovery, Physical chemistry, Thermodynamics |
Status | Grant |
Latest Schrodinger News
May 15, 2022
Summertime and the livin’ is sweatyThe bijli’s blinkin’And the warmth wave is excessive.Your discom’s bought a glitchBut your power payments The post E=MC2: Coal, power cuts & Schrodinger’s Cat appeared first on Pehal News.
Schrodinger Web Traffic
Schrodinger Rank
When was Schrodinger founded?
Schrodinger was founded in 1990.
Where is Schrodinger's headquarters?
Schrodinger's headquarters is located at 120 West 45th Street, New York.
What is Schrodinger's latest funding round?
Schrodinger's latest funding round is IPO.
How much did Schrodinger raise?
Schrodinger raised a total of $162M.
Who are the investors of Schrodinger?
Investors of Schrodinger include Ono Pharmaceuticals, Sanofi, Pavilion Capital, Laurion Capital Management, Michael Antonov and 9 more.
Who are Schrodinger's competitors?
Competitors of Schrodinger include Citrine Informatics, Modulus Discovery, DEARGEN, InstaDeep, Redesign Science and 9 more.
You May Also Like

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong developing a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties and generate synthetic data.

Acellera is a computational drug discovery company that develops ACEMD, a solution for building, simulating, and analyzing molecular systems, and PlayMolecule, a platform that offers molecular dynamics and machine learning applications for drug discovery with a specific focus on drug design.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

XtalPi is a cloud-based technology company that solves drug polymorphism by providing accurate computational crystal structure prediction for small-molecule drugs.

GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.